SANTA ANA, Calif., June 9, 2016 /PRNewswire/ -- On March 29, 2016 TransBioTec, Inc. (IMLE) was granted Patent # US 9,296,298 B2 by the U.S. Patent and Trademark Office. The title of the patent is: Alcohol Detection for Vehicle Driver Testing with Integral Temperature Compensation.
With the new patent, TransBioTec, Inc. continues to develop its Intellectual Property portfolio around its SOBR technology. The SOBR ignition interlock unit is designed to test the operator by having the operator place their finger on the SOBR sensor before the vehicle can be started. The unit is preset to an ethanol alcohol concentration level specified by the fleet owner. Before the vehicle can be started the operator must test using the SOBR device. If the test results are over the preset level, the unit will block the vehicle's ignition signal. TransBioTec, Inc. is also developing a handheld device, using the SOBR technology, for use with various other applications. TransBioTec's mission is to reduce alcohol related deaths, injuries and property damage.
About TransBioTec, Inc.
TransBioTec, Inc. has developed and patented a non-invasive alcohol sensing system ("SOBR") which includes an ignition interlock. The alcohol sensing system offers a unique solution to the national drunk driving problem that can now be applied to new markets. SOBR consists of two parts: an ethanol alcohol detection system and an ignition interlock device connected through a microprocessor. SOBR detects the ethanol alcohol level of the operator and does not allow the vehicle or equipment to start if the ethanol alcohol level is above a preset limit. In addition, random real-time monitoring also ensures that the operator cannot continue to operate a vehicle with an unsafe alcohol level. TransBioTec is currently developing a handheld application that can be applied to several different markets.
Forward Looking Statement
TransBioTec, Inc.'s statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in TransBioTec, Inc.'s filings with the Securities and Exchange Commission, including TransBioTec, Inc.'s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/transbiotec-inc-announces-the-issuance-of-a-new-patent-on-its-sobr-technology-300281989.html
SOURCE TransBioTec, Inc.